Understanding clinical trials in the UK

A clinical trial is a research study designed to test whether a treatment, test, device or care approach is safe and effective. In the UK, legitimate trials should have ethics review, clear consent, eligibility criteria, safety monitoring and a public record or identifiable sponsor. The key is to understand what phase the trial is in, what you might receive, what visits and risks are involved, and what happens to your usual care if you join.¹

What type of trial is it?

The word "trial" covers many designs. A phase 1 medicines trial is often about safety, dose and how the body handles a drug. Phase 2 looks more closely at early evidence of effect and side effects. Phase 3 compares a treatment in larger groups, often against standard care or placebo. Phase 4 follows treatments after approval. Not every study fits neatly into this phase structure, especially devices, surgery, diagnostics, digital health and behavioural interventions.

NHS clinical trials guidance explains that trials help test new medicines, treatments and procedures, and that people may be invited to take part by a healthcare professional or find trials themselves.¹ For a patient, the practical question is not just the phase. It is the risk-benefit balance for your situation.

Some trials are interventional: the study changes what happens to you. Others are observational: researchers collect information while care continues as normal. Some involve extra scans, blood tests, questionnaires, genetic testing, wearable devices or long follow-up. The burden matters. A "simple" study can still involve travel, time off work, childcare, side effects or anxiety while waiting for results.

Eligibility is not personal approval or rejection. It is a safety and design filter. A trial may exclude you because your kidney function, pregnancy status, previous treatments, cancer stage, blood pressure, infection risk or other medicines would make the intervention unsafe or the results hard to interpret. If you are excluded, ask whether another study, standard treatment or later screening window is more appropriate.

Consent, randomisation and placebo

Informed consent should be clear, unpressured and documented. The Health Research Authority says participant information and consent should help people make an informed choice about taking part.³ You should have time to read the information sheet, ask questions, discuss with family or clinicians, and understand what happens if you decline.

Randomisation can feel uncomfortable because it removes choice. But it is often what makes the result reliable. If the sickest people all choose one treatment and the healthiest choose another, the comparison becomes biased. Randomisation spreads known and unknown factors more fairly between groups.

Placebo is not always used, and it should not mean being abandoned. In many serious conditions, placebo is added to standard care or compared where no proven treatment exists. Ask whether any active treatment will be withheld, what rescue treatment exists, and whether the study has stopping rules if your condition worsens.

Safety and approvals in the UK

UK health research usually needs appropriate approvals before it starts. The Health Research Authority explains when Research Ethics Committee review is needed.⁴ Medicines trials have additional regulatory requirements, and MHRA guidance covers managing authorisations and reporting safety issues for clinical trials of medicines.⁵

Approval does not mean the intervention is risk-free. It means the study has been reviewed against research standards. Early-phase trials can carry more uncertainty. Later-phase trials may have more human data but still involve side effects, inconvenience or a treatment that may not work for you.

Ask who monitors safety, what side effects are expected, what serious adverse events have occurred so far, how emergencies are handled, and who pays for treatment if harm occurs. For cancer trials, Cancer Research UK explains clinical-trial stages and what taking part can involve.⁸ The same general principles apply across many specialties: understand the design before you consent.

Data use also matters. The consent form should explain what data is collected, who can access it, whether samples may be stored for future research, whether genetic testing is involved, and how confidentiality is protected. Ask whether clinically important incidental findings would be returned to you, because research tests are not always handled like routine NHS diagnostics.

Costs should be explicit. Some studies reimburse travel, parking or time. Others do not. Some require frequent weekday visits or overnight stays. If you are self-employed, caring for someone, disabled, or travelling a long distance, practical burden can decide whether participation is realistic. It is reasonable to ask before consenting.

Questions before you enrol

The best trial decision starts with your goal. Are you trying to access a new treatment, contribute to research, get closer monitoring, or find an option after standard treatment has failed? Those are different reasons, and each has different trade-offs.

Also ask what happens after the trial ends. Will you be told your allocation? Will you receive a summary of results? If the treatment helps you, can you keep accessing it? If the trial finds no benefit, who discusses the next standard option? These questions are especially important for rare disease, cancer and chronic conditions where treatment pathways are already stressful.

Use the Start here page to prepare an appointment, and bring your diagnosis, stage or severity, previous treatments, medicines, allergies, pregnancy status, test results and practical limits. The stack builder can help you list medicines and supplements before a trial screening visit.

If possible, show the participant information sheet to your usual GP, consultant or specialist nurse before signing. They can spot clashes with your current care before anything changes clinically.

How to find trials safely

NIHR Be Part of Research lets people search for UK health and social care research opportunities.² ISRCTN is a clinical trial registry, and ClinicalTrials.gov is an international registry.⁶⁷ Registries are useful because they show sponsors, eligibility criteria, locations, outcomes and status. They are not endorsements that a trial is right for you.

Be cautious with adverts that promise access to a "miracle treatment", demand large upfront payments, avoid naming a sponsor, will not provide a protocol or participant information sheet, or ask you to stop usual treatment without speaking to your clinician. Use the insights section to pressure-test claims, and use the health library to understand standard care for your condition before comparing it with the trial offer.

A legitimate trial should make uncertainty explicit. If the marketing sounds certain, the consent process probably is not doing its job.

If you find a trial abroad, be even more methodical. Check the registry entry, sponsor, ethics approval, hospital accreditation, costs, insurance, aftercare in the UK, language support and what happens if complications occur after you travel home. A trial can be legitimate and still be a poor fit for your practical life.

This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.